Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune cell therapy shows promise for Tough-to-Treat lymphoma

NCT ID NCT04673617

Disease control Sponsor: Artiva Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tested a new therapy called AB-101, made from natural killer (NK) cells, in 45 people with B-cell non-Hodgkin lymphoma that had come back or stopped responding to treatment. The study looked at AB-101 alone or combined with other drugs like rituximab or chemotherapy. The goal was to check safety and see if the treatment could shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AB-101 (natural killer cell therapy)
What this could lead to
If successful, this could lead to a new treatment option for patients with hard-to-treat B-cell non-Hodgkin lymphoma that has not responded to standard therapies.
What could go wrong
This is an early-phase trial with only 45 participants, so results may not apply to all patients. The therapy may cause side effects or fail to show meaningful anti-cancer activity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

45 people

The number who actually took part.

Started

Mar 2021

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of aggressive NHL of B-cell origin. For enrollment into the DLBCL specific cohort: DLBCL, High-grade B-cell Lymphoma or PMBCL. * Patient must have progressed or demonstrated intolerance to at least two lines of FDA-approved therapies, one of which must have included anti-CD20 monoclonal antibody therapy. The following are permitted: Prior autologous hematopoietic stem cell transplantation, prior treatment with FDA-approved CAR-T therapy, and/or prior treatment with an investigational agent. Prior treatment(s) with an FDA-approved CAR-T cell therapy or other cell therapies is permitted as long the patients are not considered to be refractory to this previous cell therapy approach (defined as progression within 120 days from the infusion of the cell therapy approach). * Patient must have disease that allows for response assessment using the Lugano classification criteria. * Ability to understand and sign the ICF. Exclusion Criteria: * Active CNS lymphoma or CNS involvement unless there is a history of at least 3 months of sustained remission of treated disease. * History of clinically significant structural cardiac disease. * Cardiac ejection fraction of \< 45% on echocardiogram or MUGA scan at screening assessment. * Inadequate pulmonary function. * History of a solid organ allograft, or an inflammatory or autoimmune disease likely to be exacerbated by IL-2. * Ongoing uncontrolled systemic infections. * Positive HIV PCR test * Positive for Hepatitis B or Hepatitis C * Prior allogeneic stem cell transplant. * Females of childbearing potential must be willing and able to use appropriate contraception for duration of trial and for 6 months following final AB-101 dose. Males must be sterile or commit to using appropriate contraception until 90 days following the final dose of AB-101. * Individuals who are pregnant or lactating are ineligible. * Patients who received a previous genetically modified cell therapy product (e.g., CD19 CAR-T), and progressed within 120 days from the time of the cell therapy infusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Non-Hodgkin lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Non-Hodgkin lymphoma

Contacts and locations

Locations

  • Artiva Clinical Trial Site

    Birmingham, Alabama, 35249, United States

  • Artiva Clinical Trial Site

    Tucson, Arizona, 85719, United States

  • Artiva Clinical Trial Site

    Orange, California, 92868, United States

  • Artiva Clinical Trial Site

    San Diego, California, 92093, United States

  • Artiva Clinical Trial Site

    Gainesville, Florida, 32608, United States

  • Artiva Clinical Trial Site

    Atlanta, Georgia, 30342, United States

  • Artiva Clinical Trial Site

    Chicago, Illinois, 60612, United States

  • Artiva Clinical Trial Site

    Iowa City, Iowa, 52242, United States

  • Artiva Clinical Trial Site

    Wichita, Kansas, 67214, United States

  • Artiva Clinical Trial Site

    Louisville, Kentucky, 40241, United States

  • Artiva Clinical Trial Site

    Detroit, Michigan, 48201, United States

  • Artiva Clinical Trial Site

    Lake Success, New York, 11042, United States

  • Artiva Clinical Trial Site

    New York, New York, 11021, United States

  • Artiva Clinical Trial Site

    Columbus, Ohio, 43214, United States

  • Artiva Clinical Trial Site

    Portland, Oregon, 97239, United States

  • Artiva Clinical Trial Site

    Philadelphia, Pennsylvania, 19107, United States

  • Artiva Clinical Trial Site

    Philadelphia, Pennsylvania, 19111, United States

  • Artiva Clinical Trial Site

    Providence, Rhode Island, 02903, United States

  • Artiva Clinical Trial Site

    Dallas, Texas, 75246, United States

  • Artiva Clinical Trial Site

    Salt Lake City, Utah, 84112, United States

  • Artiva Clinical Trial Site

    Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.